ArticleScientific reports2017
Long Term Glaucoma Drug Delivery Using a Topically Retained Gel/Microsphere Eye Drop.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 67 citations in OpenAlex.
- Microenvironment-Responsive Drug Delivery Systems for Ocular Surface Diseases: Mechanisms, Applications, and Translational Challenges.Small science · 2026Review
- rAAV prostaglandin-based gene therapy lowers intraocular pressure and preserves optic nerve health in glaucomatous DBA/2J mice.bioRxiv : the preprint server for biology · 2026Article
- Development of Autologous Serum Ocular Insert for Chronic Dry Eye Disease.Pharmaceutics · 2026Article
- Development of Brimonidine-Loaded Ethosomes for Glaucoma: Investigation of Intraocular Pressure-Lowering Potential In Vivo.Pharmaceutics · 2026Article
- Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems.International journal of molecular sciences · 2026Review
- Metabolism-Regulating Microspheres: Design Principles, Therapeutic Applications Across Multisystem Diseases, and Future Perspectives.Research (Washington, D.C.) · 2026Review
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Topical Gel/Microsphere Eyedrop for Combined Delivery of Brimonidine and Timolol: A Comparative Study With Traditional Eye Drops in Rabbits.Translational vision science & technology · 2025Article
- Emerging trends in long-acting sustained drug delivery for glaucoma management.Drug delivery and translational research · 2025Review
- Unraveling the Mechanisms, Clinical Impact, Comparisons, and Safety Profiles of Slow-Release Therapies in Glaucoma.Pharmaceutics · 2025Review
- Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing.Pharmaceutics · 2025Article
- Recent Advances in Smart Polymers-Based Therapeutics in Ophthalmology.International journal of nanomedicine · 2025Review
- Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.Frontiers in medicine · 2025Review
- Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Polymer-Based Self-Assembled Drug Delivery Systems for Glaucoma Treatment: Design Strategies and Recent Advances.Polymers · 2023Review
- Controlled Release of Mesenchymal Stem Cell-Conditioned Media from a Microsphere/Gel-Based Drug Delivery System for Wound Healing of Tympanic Membrane Perforations.Journal of tissue engineering and regenerative medicine · 2023Article
- Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.Annals of medicine · 2022Article
- Glaucoma Treatment and Hydrogel: Current Insights and State of the Art.Gels (Basel, Switzerland) · 2022Review
- Novel Combined Lidocaine/Povidone Iodine Delivery System for Preintravitreal Injection.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Article
- A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability.Drug delivery and translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this study was to characterize and determine the efficacy of a long-term, non-invasive gel/microsphere (GMS) eye drop for glaucoma. This novel drug delivery system is comprised of a thermoresponsive hydrogel carrier and drug-loaded polymer microspheres. In vitro release of brimonidine from the GMS drops and gel properties were quantified. A single brimonidine-loaded GMS drop was administered to 5 normotensive rabbits and intraocular pressure (IOP) was monitored for 28 days. Here we report that IOP reduction in rabbits receiving a single brimonidine GMS drop was comparable to that of rabbits receiving twice daily, standard brimonidine drops. GMS drops were retained in the inferior fornix in all animals for the length of the study. Our results suggest in vivo efficacy over 28 days from a single GMS drop and a potential decrease in systemic absorption, based on a lack of substantial IOP effects on the fellow untreated eye, compared to brimonidine twice-daily eye drops. To our knowledge, this represents the first long-term, drug-releasing depot that can be administered as a traditional eye drop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.